Other News To Note
Friday, May 27, 2011
Peregrine Pharmaceuticals Inc., of Tustin, Calif., presented data at the 10th Annual Informa Life Sciences Recombinant Antibodies Conference in Barcelona, Spain, which showed that phosphatidylserine-targeting antibodies overcame the immunosuppression in tumors that prevents immune responses to tumor cells. Antibody treatment of tumor-bearing mice caused the differentiation of highly immunosuppressive myeloid-derived suppressor cells into functional immune cells, notably M1 macrophages and dendritic cells, the company said.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.